Materiality analysis

In order to identify the material non-financial topics relevant to our stakeholders as well as to our long-term business success, we once more conducted a materiality analysis as defined in the G4 Guidelines of the Global Reporting Initiative (GRI). This process involved identifying the important issues, prioritizing them, and validating them with our Corporate Responsibility (CR) Committee.

In the first step, we identified more than 70 current CR topics for the pharmaceutical and chemical industries. For this, we used various information sources, including our experience from previous materiality analyses and CR reports, the health care sector standards of the Sustainability Accounting Standards Board (SASB), analyses of capital market requirements, and the dialogues with various stakeholders.

We discussed the options internally and narrowed it down to 46 issues, which became the focus of an online international survey conducted on some of our stakeholders. We asked participants to rank how relevant the 46 topics are to Merck KGaA, Darmstadt, Germany, as well as to rate the company's performance with regard to them. Around 120 people from across 30 countries took part in the survey; two-thirds were internal stakeholders and one-third were external stakeholders. Among them were rating agencies, suppliers, scientists, researchers, and employees involved in corporate responsibility, as well as representatives from the political arena, non-governmental organizations, and federations. In assessing the results, we gave equal consideration to the responses of all stakeholders.

In particular, participants rated product responsibility as being especially important, and they overwhelmingly rated Merck KGaA, Darmstadt, Germany's performance in this area as good to very good. Combined with other analysis results, the stakeholders' responses showed us what they think of our CR performance, as well as which aspects they consider relevant to us. The stakeholders' responses were also utilized in our 2014 Materiality Analysis.

During a materiality workshop, representatives from the CR Committee validated the top-ranked issues, discussed the strengths and weaknesses of the management system the company uses to steer topics, and identified areas that we need to address. This resulted in 27 issues that are material to Merck KGaA, Darmstadt, Germany, which are also the focus of this CR Report. These coincide for the most part with topics that we identified in previous materiality analyses. This report describes our management approach to these 27 issues of particular importance to our stakeholders and company, and provides details on measures, achievements, challenges, and goals for some of them.

The results of the materiality analysis are presented in the 2014 materiality matrix.

Materiality matrix

Click and draw a rectangle to zoom in

[undefined]
Materiality Analysis (graphic)

Because our stakeholders expect transparent reporting on more than just these 27 topics, our report includes other topics as well, which will be re-assessed in future materiality analyses.

The following table shows where topics identified as material are relevant along the value chain: upstream in our supply chain, in the course of our activities, or downstream, i.e. customers and patients.

The table furthermore indicates to which of Merck KGaA, Darmstadt, Germany's businesses and external stakeholders the topic applies. The topics are linked to the respective chapters in this report.

Material topics

Relevance along the value chain

Upstream activities

Internal activities by business sector

Downstream activities

Material for the following stakeholders

Healthcare

Life Science

Performance Materials

Group-wide topics

Compliance

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Product responsibility

Medicines to combat rare and neglected diseases

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Counterfeit medicines

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Bioethics

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Disposal and recycling of chemicals, single-use products and other products

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Interaction with players in the health industry

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Labeling of chemicals

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Clinical trials

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Pricing

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Product innovations and sustainable product design

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Product quality

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Product safety

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Transport and storage safety

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Drug safety

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Access to health

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Employees

Employee engagement

 

 

Customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Occupational health & safety

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Good leadership

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Recruiting and retaining talent

 

 

Customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Diversity and equal opportunity

 

 

Capital market community, customers, suppliers / service providers, policy makers, business associations, scientists and researchers

Advanced training and continuing education

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Environment

Waste prevention and recycling

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Energy efficiency

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Process and plant safety

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Greenhouse gas emissions

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Supply chain

Social standards in the supply chain

 

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

Environ­mental standards in the supply chain

 

 

 

 

Capital market community, customers, suppliers / service providers, NGOs / civil society, policy makers, business associations, scientists and researchers

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.

In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

Chart Generator

Interactive chart tool

Relevant Indicators

GRI

The GRI box shows all relevant indicators on this specific page.

G4-18, G4-19, G4-20, G4-21
GRI-Index